February 21, 2018 21:00 - 22:00 UTC

(Feb 21 16:00 EST/Feb 22 8:00 AEDT)



Alex C. Spyropoulos "Perioperative management of patients on chronic warfarin therapy"

This presentation with help practitioners manage patients on chronic warfarin therapy in elective periprocedural settings. It will include recommendations on the periprocedural timing of interruption and resumption of warfarin, INR monitoring, and use of heparin bridging therapy, if appropriate.

Geoff Barnes "Perioperative management of patients on chronic direct oral anticoagulant therapy"

This presentation will discuss the safe use of direct oral anticoagulation (DOAC) before and after surgical procedures, including efforts to standardize care delivery. It will review published evidence and ongoing clinical trials of periprocedural DOAC management.


Jessica Cohen


Supported by an unrestricted educational grant from: Instrumentation Laboratory

Session date: 
Tuesday, February 6, 2018 - 3:00pm to 4:00pm
ISTH Webinar Library
Carrboro, NC 27510
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

The ISTH webinar series will provide high quality and state of the art education to practitioners around the world. Throughout the course of the year, the series will provide both clinical and basic science education in the areas of Thrombosis and Anticoagulation; Platelets and Vascular Biology; Coagulation and Bleeding Disorders.

Target audience: 
  • Trainees
  • Early career professionals
  • Experience physicians needing an update who treat patients receiving warfarin or DOACs
Learning objectives: 
  1. To apply both thrombotic and bleed risk stratification strategies in periprocedural settings in devising an overall periprocedural plan for patients on chronic warfarin or on chronic direct oral anticoagulant therapy undergoing elective procedures or  surgeries
  2. To learn optimal timing of periprocedural  interruption and resumption of warfarin therapy, INR monitoring, and potential use of warfarin reversal agents
  3. To learn optimal timing of periprocedural interruption and resumption of direct oral anticoagulant therapy, laboratory monitoring, and potential use of reversal agents
  4. To assess the potential use (and potential harm) of periprocedural heparin bridging therapy
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD, MSc
Meera Chitlur, MD
Caterina Casar, PhD

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  




Geoffrey Barnes, MD, MScBMS/Pfizer, NHLBI, Blue Cross Blue Shield of Michigan, Portola JanssenResearch Investigator, Consultant
Meera Chitlur, MDBayer, Genentech, Novo nardisk, BaxterAdvisory Board, Consultant, Speaker
In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved




Alex Spyropoulos, MD

Geoff Barnes, MD

CME Coordinator Contact Information

Lacey Schmeidler
Phone number: 
+1 (919) 929-3807